Skin (FLACC Scores of Test Subjects) After Tape Removal Clinical Trial
Official title:
Adhesive Tape Trauma Evaluation of a New Gentle Tape in Healthy Infant Subjects
| Verified date | July 2020 |
| Source | 3M |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The objective of this study is to determine the relative gentleness of a new medical tape.
| Status | Completed |
| Enrollment | 24 |
| Est. completion date | March 20, 2018 |
| Est. primary completion date | January 23, 2018 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 6 Months to 4 Years |
| Eligibility |
Inclusion Criteria: Subjects will be infants or children of either gender who meet the
following criteria: 1. Who are healthy and who have intact skin at the test site with a baseline score of 0 for erythema 2. Who are between the ages of 6 months - 4 years of age (48 months) 3. Who have a Fitzpatrick Skin Type of I, II or III 4. Whose parent or legal representative agrees to not use any products (i.e. topical medications, creams, powders or ointments) on the test sites for 24 hours prior to the study start date 5. Whose parent or legal representative agrees to sponge bathe their child during the study but agrees to not bathe their child 1 hour before each visit. 6. Whose parent or legal representative agrees to not soak the tape during a sponge bath. If the site gets wet, parent or legal representative agrees to pat their child's back dry (no rubbing). 7. Whose parent or legal representative is willing to sign the Informed Consent Form (with photo release) and HIPAA Authorization. Exclusion Criteria: 1. Who are known to be developmentally delayed 2. Who have any known allergy or sensitivity to tapes 3. Who have sunburn, skin infection or scars, moles, or other blemishes on the back that would obscure grading of the test site 4. Who have had any exposure to other topical medications, creams, powders, or ointments on the test sites 24 hours prior to the start of the study 5. Who have had a strep infection within the 2 weeks prior to the start of the study 6. Who have a history of uncontrolled diabetes, psoriasis, any active dermatitis, or recent history of dermatitis or skin reactions 7. Has participated in any study in the last 2 weeks, or are currently participating in another study, or are scheduled to participate in another study during this study period. 8. Has any other skin disorders that, in the opinion of the investigator, will interfere with the study results or will increase undue risk for the child. |
| Country | Name | City | State |
|---|---|---|---|
| United States | cyberDERM, inc. | Broomall | Pennsylvania |
| Lead Sponsor | Collaborator |
|---|---|
| 3M |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | The Face, Legs, Activity, Cry, Consolability (FLACC) Score. | The Face, Legs, Activity, Cry, Consolability (FLACC) scale is a measurement used to assess pain for children Participants between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. The scale is scored in a range of 0-10 with 0 representing no pain. Lower values represent lessening pain on the scale. At the 24 hour visit , a baseline FLACC score was recorded with the tape still in place. The tape was then removed and a FLACC score was recorded after removal. The reported value is the difference between FLACC after removal and FLACC at baseline. | 24 Hours after initial tape application and after tape removal. Change in FLACC score between the time of tape removal and baseline. |